Food Neophobia in Patients With Phenylketonuria

Tassia Tonon, Chenia Martinez, Soraia Polonia, Tatiele Nalin, Anita MacDonald, Ida Vanessa D. Schwartz

Abstract

Background: In phenylketonuria (PKU), only a limited range of natural foods, such as fruits, vegetables, oils and sugars, can be consumed without restrictions. The present study aimed to study if food neophobia (i.e. an unwillingness to eat novel food) occurs in patients with PKU and to compare in non-PKU healthy controls and to identify any associated factors.

Methods: This cross-sectional case-control study used a convenience sampling strategy to recruit patients diagnosed with PKU and healthy controls matched by gender and age. Patients and controls were invited to complete the food neophobia scale (FNS) questionnaire, and clinical and treatment data were collected through a review of medical records.

Results: Twenty-five patients (mean age 19.3 ± 4.7 years, 13 women) with PKU and 25 controls (mean age 19.9 ± 4.9 years; P = 0.676, 13 women) were evaluated. The mean age of treatment onset in patients with PKU was 52.8 ± 29.7 days. The mean FNS score of patients with PKU was significantly higher (47.2 ± 9.7) than controls (29.4 ± 12.5, P < 0.001). Food neophobia was associated more with male gender (P = 0.039).

Conclusions: Food neophobia is frequent in patients with PKU. It does not appear to be associated with female gender, with Phe levels and not just in children.

Keywords: Phenylketonuria; Food neophobia; Inborn errors of metabolism

Introduction

Phenylketonuria (PKU) is an inborn error of metabolism with an autosomal recessive inheritance pattern caused by the presence of mutations in the gene that codes for phenylalanine hydroxylase (PAH, EC 1.14.16.1). PAH catalyzes the conversion of phenylalanine (Phe) to tyrosine by means of a reaction dependent on tetrahydrobiopterin, iron and molecular oxygen [1]. In untreated patients, serum Phe concentrations are raised to neurotoxic levels, resulting in progressive, irreversible neurological impairment [2, 3]. The worldwide prevalence of PKU is estimated at 1 per 10,000 live births [4]. In Brazil, the most recent survey found a prevalence of 1 per 24,780 newborns [5].

The treatment consists of a Phe-restricted diet and supplementation with a Phe-free metabolic formula to ensure adequate intake of other amino acids and micronutrients. If a strict diet is started early (ideally before 10 days of life) and maintained carefully, normal development is expected [2]. Although nutritional management is effective, only a very limited range of natural foods can be offered without any restrictions; these include fruits, vegetables, fats and sugars [6]. In Brazil, medical foods with low Phe content are not provided by the public health system. Although they can be bought independently, their out-of-pocket cost is high and availability is limited, contributing to a lack of variety in the diet of PKU patients.

According to MacDonald and colleagues (1994), it is important to support the development of normal eating behavior in patients with PKU, within the limits of dietary management, so that all their nutritional needs are met [6]. Food neophobia, defined as an unwillingness to eat novel foods [7], may further limit the variety of foods and, consequently, nutrients ingested by patients with PKU [6]. In recent years, neophobic eating behavior in the general population has been investigated since it can affect dietary preferences, food quality and variety, thus increasing the risk of developing several chronic diseases [8].

However, to date, little is known about the relationship between the presence of food neophobia in patients with PKU and clinical and treatment-related variables, such as age, blood Phe control, anthropometry, lifestyle measures, breastfeeding in infancy and age of solid introduction of foods. Within this context, the present study aimed to compare the presence of food neophobia in patients with PKU and in non-PKU controls and to elucidate the factors possibly associated with this condition.
Food neophobia was evaluated through the food neophobia scale (FNS), a questionnaire first developed in English by Pliner and Hobden (1992) [7] and later translated into Portuguese and validated for use in Brazil by Previato (2015) [8]. The FNS consists of a 10-item self-report questionnaire. A high average score (obtained by adding the individual scores of each item on a Likert-type scale) indicates less willingness to try new foods (neophilia), while a low average score indicates greater willingness to try new foods (neophilia). Individuals with scores ≤ 16.4 were classified as neophobic, those with scores between 16.5 and 38.5 were considered neutral and those with scores > 38.6 were classified as neophobic [8]. Additionally, patients and controls were asked about their self-perception about the rejection of new foods through a specific question: “Do you reject new foods?”

Statistical analyses were carried out in PASW Statistics, version 18.0 (SPSS Inc., Chicago, IL). Descriptive analysis consisted of absolute frequencies. Continuous variables were expressed as mean and standard deviation. Student’s t-test and the Chi-square test for paired or independent samples were used. For the univariate analyses presented in the chart, Fisher’s exact test was used. The level of significance was set at 5%.

Results

Fifty participants (25 patients and 25 controls) were included in this study (Table 1). In the patient group, the mean Phe levels were 1360.3 ± 671.3 µmol/L at diagnosis and 710.5 ± 346.4 µmol/L in the 12 months prior to the study (range, 215.1 - 1,408.9). The mean age at treatment onset was 52.8 ± 29.7 days.

No patient was exclusively breastfed due to treatment, while 21 controls had exclusive breastfeeding until 6 months of age. No patients and controls report being smokers.

According to the FNS, 20 patients and seven controls were classified as neophobic (P = 0.001); five patients and 15 controls as neutral (P = 0.001); and three controls and no patients as neophilic (P < 0.001). The mean FNS score was 47.2 ± 9.7 for patients with PKU and 29.4 ± 12.5 for controls (P < 0.001).

Figure 1 shows the possible factors associated with food neophobia in patients with PKU. Female gender was the only factor significantly (P = 0.039) associated with neophobia (in this case, as a protective factor against the occurrence of food neophobia).

Discussion

In this study, a high prevalence of food neophobia was found...
among this older group of patients with PKU. Food neophobia does not appear to be associated with female gender, and is not associated with Phe metabolic control. According to Knaapila and colleagues (2007) [11], from an evolutionary point of view, food neophobia is a protective phenomenon, designed to prevent humans from eating foods that are potentially harmful to health. Thus, it is unsurprising that, in our sample, PKU patients were classified as neophobic, corroborating the findings of Evans and colleagues (2016) [12], and showing that not only children with PKU have food neophobia, but that this condition remains even in adult life.

In the past, these restrictions were recommended to PKU patients only until early adulthood, which allowed a greater variety in their choice of foods after the treatment period. Over the years, however, guidelines have been updated, and currently recommend “diet for life” [2]. In the present study, food neophobia was not only a characteristic of children, as described by Evans and colleagues (2016) [12]; it persisted even into adulthood.

Theoretically, because it allows intake of fruits and most vegetables (which do not affect metabolic control), the PKU diet is considered a healthy one. However, it is among the most restrictive of all known nutritional therapies. Given the central role of food in the life of a developing child, extremely strict dietary therapies can adversely affect the eating behaviors and nutritional status of these patients in long term [13].

Few studies have addressed this issue, but patients with PKU are known to be apprehensive when trying new foods, limiting themselves to the intake of few foods that are within their dietary restrictions. The study by Evans and colleagues (2016) [12] evaluated 35 children with PKU (age 4 - 13 years) through a parental-report questionnaire about dietary habits. Our study is novel in so far as patients were evaluated directly (they completed their own assessments), and was the first, to our knowledge, to investigate the potential association between presence of food neophobia in patients with PKU and metabolic control, as well as other variables that can influence food choices in this population. In our study, diagnosis was late in the majority of patients (mean age of treatment onset was 52.8 ± 29.7 days), unlike in the population assessed by Evans and colleagues (2016) [12], which was diagnosed by neonatal screening.

Some determinants of food neophobia

Gender and age

Hursti and Sjooeden (1997) [14] reported higher rates of food neophobia in healthy boys when compared to girls (n = 722, age 7 - 17 years). Greater food neophobia was also observed in the children’s fathers as opposed to their mothers. In a recent German study which evaluated adolescents, food phobia levels did not differ between boys and girls [15], but the authors noted that food phobia levels between the sexes were age-dependent. The literature shows that, in childhood and adulthood, men appear to be more neophobic, whereas Cooke and Wardle (2005) [16], who evaluated 1,291 children aged 4 - 16 years, believe that in adolescence body weight and physical appearance are more relevant topics for girls, making them more neophobic than boys. The present study is consistent with the literature, evincing a higher level of food neophobia in boys than in girls.

Phe levels

This was the first study to associate Phe levels with food neophobia in patients with PKU. Good metabolic control, that is having Phe levels within reference range, was not a determinant of greater rejection of novel foods. Regarding the Phe level at diagnosis, we were unable to verify any significant influence of Phe > 1,200 µmol/L on later food neophobia; however, the sample size may have limited the
Importance of developing normal eating behavior within the \[ \text{els} \] in patients, allowing greater exposure to novel foods. The \[ \text{therapies} \] could contribute to better management of Phe lev- \[ \text{care} \] providers. We believe that the introduction of adjuvant \[ \text{challenge} \] for patients with PKU, their families and health - \[ \text{within} \] target range, without impairing dietary behavior is a \[ \text{Long-term} \] good metabolic control, that is, having Phe levels \[ \text{Conclusions} \] should be addressed as early as possible in life.

Breastfeeding and diet

Another potential determinant of food neophobia is the du- \[ \text{ration} \] of the breastfeeding period. Babies who are breastfed for longer discover new flavors as early in their first days of life, as flavors from the mother’s diet are conveyed to them via the breast milk [17]. Children who were breastfed for at least 6 months demonstrated lower levels of food neophobia compared to children with shorter breastfeeding times [18]. In addition, exclusive breastfeeding may be associated with reduced food neophobia, as early introduction of food may lead to increased gastrointestinal discomfort and food allergies [18].

The World Health Organization and the Brazilian Min- \[ \text{istry} \] of Health recommend exclusive breastfeeding for 6 months, with complementary feeding for 2 years or longer [19, 20]. However, in patients with PKU, the Phe-free meta- \[ \text{bolic} \] formula should ideally be introduced as early as the first month of life, substantially reducing their breast milk intake after diagnosis and thereby modifying their taste perceptions into childhood. The Phe-restricted diet for PKU patients is rife with obstacles, such as limited food variety, the unpalatability of the metabolic formula (which tastes strong and bitter) and the rigid dietary management routine. MacDonald and col- \[ \text{l leagues} \] (1997) [13] associated the food neophobia found in children with PKU to factors such as an innate fear of eating foods they consider “unsafe”, limited food choices, palatabil- \[ \text{ity} \] issues and a lack of appetite due to use of the metabolic formula.

We believe that use of the metabolic formula, the sig- \[ \text{nificant} \], early reduction of breast milk intake and the limited choice of foods are all factors that trigger food neophobia in patients with PKU. In Brazil, these issues are compounded by the fact that medical foods with low Phe content are not pro- \[ \text{vided} \] by the public health system. Although they can be bought independently, their out-of-pocket cost is high and availability is limited, contributing to a lack of variety in the diet of PKU patients. Furthermore, problems related to the metabolic for- \[ \text{mula} \] are frequent, such as shortages of government supply and the inability to choose more palatable formulations, making treatment even more difficult.

Food neophobia may be an issue when new treatments will be available to Brazilian patients with PKU, such as PEG- \[ \text{PAL} \] and sapropterin, designed to improve protein intake, so should be addressed as early as possible in life.

Conclusions

Long-term good metabolic control, that is, having Phe levels within target range, without impairing dietary behavior is a challenge for patients with PKU, their families and health- \[ \text{care} \] providers. We believe that the introduction of adjuvant therapies could contribute to better management of Phe lev- \[ \text{els} \] in patients, allowing greater exposure to novel foods. The importance of developing normal eating behavior within the constraints of a Phe-restricted diet, encouraging intake of a wide range of flavors to maximize healthy food choices and to promote better social interaction, cannot be underestimated. Education strategies involving programs to promote safe and healthy diets and dietary practices should be encouraged at fa- \[ \text{cilities} \] that serve PKU patients and their families.

Acknowledgments

We are grateful to the Graduate Program in Medicine: Medi- \[ \text{cal} \] Sciences at the School of Medicine, Universidade Federal do Rio Grande do Sul (UFRGS); the patients at our Center for Diagnosis, Monitoring, and Treatment of Patients with Phe- \[ \text{nylketonuria} \] in Rio Grande do Sul, Brazil; and the patients at our Center in HCPA.

Financial Disclosure

Financial support was from the Hospital de Clinicas de Porto Alegre Research and Event Incentive Fund (FIPE/HCPA).

Conflict of Interest

All authors declare "no conflicts of interest".

Informed Consent

All the research participants (patients and controls) signed the inform consent form according to the approved project under number 2015-0072 from our Institutional Review Board HCPA.

Author Contributions

Tassia Tonon: study design; data collection and interpretation; manuscript writing. Chenia Martinez: study conception; data interpretation; critical appraisal of manuscript content; final approval. Soriaa Poloni: study conception; data interpretation; critical appraisal of manuscript content; final approval. Tatiele Nalin: study conception; data interpretation; critical appraisal of manuscript content; final approval. Anita MacDonald: study conception; data interpretation; critical appraisal of manuscript content; final approval. Ida Vanessa Doederlein Schwartz: study conception; data interpretation; critical appraisal of manuscript content; final approval.

References

2. van Wegberg AMJ, MacDonald A, Ahring K, Belanger-Quintana A, Blau N, Bosch AM, Burlina A, et al. The com-
Food Neophobia in Patients With PKU

112


